New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 19, 2014
08:36 EDTACT, NVSDistrict court rules against Actavis' generic version of Novartis' Exelon
Actavis (ACT) confirmed that the U.S. District Court for the District of Delaware has found certain claims of two U.S. patents valid and infringed by Actavis' generic version of Novartis' (NVS) Exelon Patch. Actavis is reviewing the court's decision and will evaluate all available options, including an appeal. Exelon Patch is a prescription medicine used to treat people with mild to moderate dementia associated with Alzheimer's or Parkinson's disease. Actavis' Abbreviated New Drug Application for its generic version of Exelon Patch is currently pending with the FDA.
News For ACT;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 28, 2014
07:31 EDTNVSThe FDA to hold a workshop
First Annual Neonatal Scientific Workshop, "Roadmap for Applying Regulatory Science to Neonates" is being held at FDA Silver Spring, Maryland offices on October 28-29 at 8:30 am. Webcast Link
05:35 EDTNVSNovartis confirms FY14 revenue view of growth at a low to mid-single digit rate
Subscribe for More Information
05:31 EDTNVSNovartis reports Q3 core EPS $1.37, consensus $1.29
Subscribe for More Information
October 27, 2014
15:18 EDTACTEarnings Preview: Pfizer looks to new products to offset generic competition
Subscribe for More Information
10:36 EDTACTAllergan delivers earnings beat, says willing to consider higher Valeant bid
Subscribe for More Information
08:25 EDTNVSCSL to acquire Novartis' influenza vaccine business
Subscribe for More Information
07:29 EDTNVSWorldwide Business Research to hold a conference
ProcureCon Pharma 2014 is being held in Philadelphia on October 27-29.
06:28 EDTNVSVirbac acquires veterinary assets from Eli Lilly in U.S.
Virbac announces that it has entered into an agreement with Eli Lilly (LLY) to acquire "major" U.S. veterinary products currently marketed by Novartis (NVS) Animal Health. Eli Lilly has agreed to divest these U.S. assets in connection with the U.S. Federal Trade Commissionís review of Eli Lillyís pending acquisition of Novartis Animal Health worldwide. Under the terms of this agreement, Virbac would acquire a combination of titles and rights for the U.S. on trademarks, marketing authorizations, patents, know-how, customer lists and other assets, related to two parasiticides for dogs including Sentinel Flavor Tabs and Sentinel Spectrum, currently marketed in the U.S. by Novartis Animal Health. In the U.S., Sentinel Flavor tabs and Sentinel Spectrum are expected to reach total revenues of approximately $90M-$100M in 2014. Adding these brands and commercial franchise to the current Virbac portfolio of products offered to veterinary clinics and pet owners in the U.S. will strengthen Virbacís presence and penetration in the U.S. companion animal veterinary market and leverage its growth potential. The completion of this transaction is subject to approval by the Federal Trade Commission, which Virbac expects may be received in the near future. It is also conditioned on the closing of the acquisition of Novartis Animal Health by Eli Lilly and should occur shortly thereafter.
October 23, 2014
18:18 EDTACTGlenview Capital acquires stake in Actavis, Bloomberg reports
Subscribe for More Information
11:57 EDTNVSNovartis management to meet with Jefferies
Subscribe for More Information
08:10 EDTACTActavis confirms appeals court upholds Lo Loestrin Fe patent
Subscribe for More Information
05:21 EDTNVSNovartis AIN457 meets primary endpoint in two Phase III studies in AS
Novartis announced that AIN457 met primary and key secondary endpoints in two pivotal Phase III studies, MEASURE 1 and MEASURE 2, in patients with ankylosing spondylitis, or AS. Key endpoints included improvements in signs and symptoms of the disease versus placebo and associated improvements in physical function and quality of life. Secukinumab is an investigational medicine that works by stopping the action of interleukin- 17A, a protein that is central to the development of inflammatory diseases, including AS. MEASURE 1 and MEASURE 2 enrolled a combined total of approximately 600 patients. Detailed results of the studies will be presented at an upcoming medical congress. Joint regulatory applications for secukinumab in AS and PsA are planned for 2015. This follows the secukinumab global regulatory applications for moderate- to-severe plaque psoriasis which were filed in October 2013 with regulatory decisions anticipated in late 2014 or early 2015.
October 22, 2014
08:38 EDTACTActavis signs option to acquire Rhythm Health
Subscribe for More Information
07:44 EDTNVSGlaxoSmithKline backs FY14 view for core EPS 'broadly similar' to FY13
GlaxoSmithKline (GSK) continues to expect full year 2014 core EPS to be broadly similar to 2013 at CER and on ex-divestment basis. Glaxo says its proposed 3-part transaction with Novartis (NVS) is on track for completion in 1H15.
October 21, 2014
07:15 EDTNVSFDA to hold workshop on breast cancer drug development
Subscribe for More Information
06:44 EDTACTActavis among bidders for Omega Pharma, Bloomberg reports
Subscribe for More Information
October 20, 2014
18:51 EDTACTOn The Fly: After Hours Movers
Subscribe for More Information
15:09 EDTNVSNovartis reports FDA advisory committee recommends approval of secukinumab
Novartis announced the Dermatologic and Ophthalmic Drugs Advisory Committee to the FDA voted unanimously to support the approval of AIN457, or secukinumab, a selective interleukin-17A inhibitor, for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. A Biologics License Application for secukinumab is currently under FDA review with an anticipated action date in early 2015.
07:26 EDTNVSFDA Dermatologic & Ophthalmic Drugs Advisory Committee to hold a meeting
Subscribe for More Information
06:28 EDTACTAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use